Cargando…

T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma

Poor response of human malignant melanoma to currently available treatments requires a development of innovative therapeutic strategies. Their evaluation should be based on animal models that resemble human melanoma with respect to genetics, histopathology and clinical features. Here we used a trans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abschuetz, Oliver, Osen, Wolfram, Frank, Kathrin, Kato, Masashi, Schadendorf, Dirk, Umansky, Viktor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712696/ https://www.ncbi.nlm.nih.gov/pubmed/24213320 http://dx.doi.org/10.3390/cancers4020490

Ejemplares similares

c-RET Molecule in Malignant Melanoma from Oncogenic RET-Carrying Transgenic Mice and Human Cell Lines
por: Ohshima, Yuichiro, et al.
Publicado: (2010)

Mapping of Melanoma Modifier Loci in RET Transgenic Mice
por: Dragani, Tommaso A., et al.
Publicado: (2000)

Differential Regulation of MMP‐9 and TIMP‐2 Expression in Malignant Melanoma Developed in Metallothionein/RET Transgenic Mice
por: Asai, Masami, et al.
Publicado: (1999)

Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice
por: El Khoury, Diala, et al.
Publicado: (2010)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Functional RET G691S Polymorphism in Cutaneous Malignant Melanoma
por: Narita, N, et al.
Publicado: (2009)

Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene.
por: Iwamoto, T., et al.
Publicado: (1993)

Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma
por: Pin, Yeo Kim, et al.
Publicado: (2015)

Screening of Human Tumor Antigens for CD4(+) T Cell Epitopes by Combination of HLA-Transgenic Mice, Recombinant Adenovirus and Antigen Peptide Libraries
por: Osen, Wolfram, et al.
Publicado: (2010)

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment
por: Umansky, Viktor
Publicado: (2012)

Autochthonous Mouse Melanoma and Mammary Tumors do not Express the Pluripotency Genes Oct4 and Nanog
por: Schreiber, Caroline, et al.
Publicado: (2013)

Oncogene-linked in situ immunotherapy of pre-B lymphoma arising in E mu/ret transgenic mice.
por: Ichihara, M., et al.
Publicado: (1995)

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
por: Helfrich, Iris, et al.
Publicado: (2010)

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
por: Helfrich, Iris, et al.
Publicado: (2013)

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
por: Hegde, Aparna, et al.
Publicado: (2020)

Hair graying with aging in mice carrying oncogenic RET
por: Iida, Machiko, et al.
Publicado: (2020)

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020)

Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma
por: Federico, Aniello, et al.
Publicado: (2020)

A New Transgenic Tool to Study the Ret Signaling Pathway in the Enteric Nervous System
por: Bandla, Ashoka, et al.
Publicado: (2022)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
por: Wagner, Nikolaus B., et al.
Publicado: (2019)

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
por: Simon, Sonja C. S., et al.
Publicado: (2020)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Complex Formation with Monomeric α-Tubulin and Importin 13 Fosters c-Jun Protein Stability and Is Required for c-Jun’s Nuclear Translocation and Activity
por: Kappelmann-Fenzl, Melanie, et al.
Publicado: (2019)

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
por: Petrova, Vera, et al.
Publicado: (2023)

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
por: Bouwhuis, Marna G., et al.
Publicado: (2009)

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
por: Lepper, Alisa, et al.
Publicado: (2023)

Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E
por: Kordaß, Theresa, et al.
Publicado: (2018)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Immunotherapy in non-melanoma skin cancer: updates and new perspectives
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization
por: Schmutzler, Brian S, et al.
Publicado: (2011)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

MicroRNAs affecting the susceptibility of melanoma cells to CD8(+) T cell‐mediated cytolysis
por: Pane, Antonino A., et al.
Publicado: (2023)

Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice
por: Jin, L, et al.
Publicado: (2008)

Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice
por: Jin, L, et al.
Publicado: (2009)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and Survival
por: Gast, Andreas, et al.
Publicado: (2011)

Cellular immunity in human malignant melanoma and melanoma histology.
por: Cameron-Mowat, D. E., et al.
Publicado: (1973)

Cannot write session to /tmp/vufind_sessions/sess_strrdqmoebdrqnmf6dq5f38lsj